BCRX Q1 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$146M+56.9% YoY

Gross Profit

$141M96.9% margin

Operating Income

$21M14.6% margin

Net Income

$32,0000.0% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+10.6%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$480M

Total Liabilities

$932M

Stockholders' Equity

-$452M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$146M	$93M	+56.9%
Gross Profit	$141M	$91M	+54.1%
Operating Income	$21M	-$14M	+246.5%
Net Income	$32,000	-$35M	+100.1%

Revenue Segments

Product

$144M99%

Collaborative and Other Research and Development

$2M1%